11/14
09:42 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at Guggenheim.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at Guggenheim.
11/14
09:42 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at Guggenheim.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at Guggenheim.
11/14
09:08 am
mrsn
Rating for MRSN
Low
Report
Rating for MRSN
11/14
09:08 am
mrsn
Rating for MRSN
Low
Report
Rating for MRSN
11/14
07:52 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating.
11/14
07:52 am
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at Wedbush from a "strong-buy" rating to a "hold" rating.
11/13
06:12 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at William Blair to a "market perform" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at William Blair to a "market perform" rating.
11/13
06:12 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at William Blair to a "market perform" rating.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) was downgraded by analysts at William Blair to a "market perform" rating.
11/13
02:11 pm
mrsn
Mersana Therapeutics downgraded to Market Perform from Outperform at William Blair
Low
Report
Mersana Therapeutics downgraded to Market Perform from Outperform at William Blair
11/13
02:11 pm
mrsn
Mersana Therapeutics downgraded to Market Perform from Outperform at William Blair
Low
Report
Mersana Therapeutics downgraded to Market Perform from Outperform at William Blair
11/13
12:56 pm
mrsn
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at BTIG Research.
Low
Report
Mersana Therapeutics (NASDAQ:MRSN) had its "neutral" rating reaffirmed by analysts at BTIG Research.
11/13
12:43 pm
mrsn
Rating for MRSN
Low
Report
Rating for MRSN
11/13
11:54 am
mrsn
Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
Low
Report
Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
11/13
11:54 am
mrsn
Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
Low
Report
Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
11/13
10:36 am
mrsn
Mersana Therapeutics downgraded to Market Perform from Outperform at Leerink
Low
Report
Mersana Therapeutics downgraded to Market Perform from Outperform at Leerink
11/13
09:43 am
mrsn
Mersana Therapeutics downgraded to Neutral from Buy at BTIG
Low
Report
Mersana Therapeutics downgraded to Neutral from Buy at BTIG
11/13
08:04 am
mrsn
Mersana Therapeutics downgraded to Neutral from Outperform at Wedbush
Low
Report
Mersana Therapeutics downgraded to Neutral from Outperform at Wedbush
11/13
08:04 am
mrsn
Mersana Therapeutics downgraded to Neutral from Outperform at Wedbush
Low
Report
Mersana Therapeutics downgraded to Neutral from Outperform at Wedbush